Phase III data for HDM sublingual allergy immunotherapy tablet Acarizax for house dust mite allergy published in Journal of the American Medical Association- ALK
ALK has announced that The Journal of the American Medical Association (JAMA) has published results from a Phase III clinical trial evaluating the treatment of house dust mite (HDM) allergic asthma with the company's HDM sublingual allergy immunotherapy tablet (SLIT-tablet) Acarizax. The randomised, double-blind, placebo-controlled trial took place between August 2011 and April 2013 and involved 834 adult patients with HDM allergic asthma and HDM allergic rhinitis, which were not well-controlled by inhaled corticosteroids (ICS).
The trial showed that 12 SQ-HDM (the dose approved in the EU) significantly reduced the risk of a moderate or severe asthma exacerbation relative to placebo with a hazard ratio (HR) of 0.66, corresponding to a 34% risk reduction. This included a 36% reduction in risk of nocturnal awakening or increase in daily symptoms, a 48% reduction in the risk of increased use of SABA treatments and a 42% reduction in the deterioration of lung function.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins